OBJECTIVE: Thyroidectomy is associated with a high incidence of postoperative nausea and vomiting (PONV), ranging from 60% to 84%. We conducted this study to compare the antiemetic effects and safety of granisetron 20 µg/kg and ramosetron 4 µg/kg in patients undergoing elective thyroidectomy under standard anaesthetic technique.
INTRODUCTION
Postoperative nausea and vomiting (PONV) are common and distressing symptoms. 1 In previous studies, 2 the average early (within 6 hours after surgery) and late (within 48 hours) incidences of PONV were reported as 40% and 60%, respectively. Thyroidectomy is associated with relatively high incidences of PONV, ranging from 60% to 84%, 3, 4 and antiemetics such as metoclopramide or alizapride do not prevent PONV effectively. 3 Ramosetron (Nausea, Yamanouchi, Tokyo, Japan) as well as granisetron (Kytril, Smith Kline Beecham, London, UK) are selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists. Ramosetron is more potent and longer acting than granisetron against cisplatin-induced emesis. 5 Both drugs also have been used for the treatment of PONV. [6] [7] [8] [9] [10] [11] [12] They lack the sedative, dysphoric and extrapyramidal symptoms associated with other traditional antiemetics, such as droperidol and metoclopramide. 13 The lack of associated side-effects makes the use of 5-HT 3 pyridostigmine 0.03 mg/kg i.v. at the end of surgery. The patient was extubated when fully awake. Placement of a nasal or oral gastric tube during surgery was not permitted. Anaesthesia duration was defined as the period from induction until the discontinuation of nitrous oxide and was recorded for all patients. Postoperative analgesia consisted of 30 mg tarasyn, as required.
After completion of surgery, all episodes of PONV (nausea, retching or vomiting) were recorded during the first 24 hours after anaesthesia, covering two time periods (0-1 h in the postanaesthesia care unit and 1-24 h in the general ward). Specially trained nurses performed the questioning, and they were blinded to study the groups. In the post-anaesthesia care unit and general ward, recordings were performed every 30 minutes and 6 hours, respectively. Nausea was defined as a subjective, unpleasant sensation associated with awareness of the urge to vomit. Retching was defined as laboured, spastic, rhythmic contraction of the respiratory muscles without the expulsion of gastric contents, and vomiting was defined as the forceful expulsion of gastric contents from the mouth. 14 Retching or vomiting was recorded as either present or absent. If the patient had nausea, the severity of the episode was recorded during each assessment period using the following scale: 1 = mild nausea, 2 = moderate nausea and 3 = severe nausea. The highest score during each assessment period was recorded. A rescue antiemetic (e.g., metoclopramide 10 mg i.v. or i.m.) was allowed at the request of the patient or upon the advice of a doctor. Adverse events were recorded during the 24-hour postoperative period. Patients were questioned specifically about any possible side-effects of the study medication and then asked to volunteer any other complaints.
Statistical analyses of the data between groups were performed by one-way analysis of variance (ANOVA) with Bonferroni's correction for multiple comparisons, the chi-square test or Fisher's exact probability test, as appropriate. P < 0.05 was considered significant. All values were expressed as mean ± SD or number (%).
RESULTS
A total of 113 patients were recruited. The numbers of patients receiving placebo, granisetron and ramosetron were 41, 36 and 36, respectively. There were no significant differences in patient characteristics ( Table 1) .
The incidence of PONV during the first hour after anaesthesia was 36.6%, 11.1% and 25.0% in patients receptor antagonists attractive. Nonetheless, they are expensive compared with traditional antiemetics. 6 Furthermore, the incidence of drug-related side effects, such as headache, increases in a dose-dependant manner. 2 Therefore, it is necessary to discover the lowest dose required for preventing PONV. In previous studies, 7-9,11 granisetron 40 µg/kg and ramosetron 0.3 mg were re-ported as minimum effective doses for preventing PONV. However, there are a few reports using lower dosages of the two drugs.
This prospective, randomized, double-blind study was designed to compare the efficacy of ramosetron (4 µg/kg) with granisetron (20 µg/kg) in preventing PONV in patients undergoing thyroidectomy under standard anaesthetic technique.
PATIENTS AND METHODS
After approval by the local Ethics Committee and obtaining informed consent from patients, we studied 113 ASA physical status I or II patients, aged between 18 and 65 years, undergoing general anaesthesia for elective thyroidectomy. Patients who were more than 50% over ideal body weight, those who had gastrointestinal diseases and had taken antiemetics within 24 hours prior to surgery were excluded from the study. Patients were premedicated with midazolam 0.05mg/kg and glycopyrrolate 0.004 mg/kg.
A medical history (including previous motion sickness, prior PONV) was recorded along with demographic information such as age, height and weight.
Patients were randomly allocated to receive placebo (0.9% NaCl), granisetron 20 µg/kg or ramosetron 4 µg/kg i.v. over 2-5 minutes immediately before the induction of anaesthesia. All antiemetics were diluted with normal saline (0.9% NaCl) to a total volume of 10 ml. Anaesthesia was induced with thiopentone 5 mg/kg i.v. and vecuronium 0.1 mg/kg or succinylcholine 1-1.5 mg/kg i.v. was used to facilitate tracheal intubation. After intubation, anaesthesia was maintained with 1.5%-2.5% (inspired concentration) enflurane and 50% nitrous oxide in 50% oxygen. Ventilation was mechanically controlled and was adjusted to maintain an end-tidal concentration of carbon dioxide of between 3.5 kPa and 4.5 kPa throughout surgery with an anaesthetic/respiratory analyzer (Dräger, Lübeck, Germany). Muscle relaxation was achieved with vecuronium or pancuronium and antagonized by a combination of glycopyrrolate 0.002 mg/kg i.v. and GRANISETRON OR RAMOSETRON IN THYROIDECTOMY who had received placebo, granisetron 20 µg/kg and ramosetron 4 µg/kg, respectively. The incidence of PONV was significantly lower in the granisetron group than in the placebo group (p = 0.012). The corresponding incidences during 1-24 hours after anaesthesia were 51.2%, 30.6% and 41.7%, respectively. There were no significant differences between the three groups (p > 0.05). Overall, the corresponding incidences of PONV during the 0-24-hour period after anaesthesia was 61.0%, 30.6% and 50.0%, respectively, with a significantly lower value in the granisetron group than in the placebo group (p = 0.008) ( Table 2 ).
The incidence of nausea during 0-1 hour after anaesthesia was 29.3%, 11.1% and 22.2% in patients who had received placebo, granisetron 20 µg/kg and ramosetron 4 µg/kg, respectively. There was a significant difference between the granisetron and the placebo groups (p = 0.045) ( Table 2 ).
The incidence of vomiting during 1-24 hours after anaesthesia and the entire 24 hours was significantly lower (p = 0.036 and 0.021) in the granisetron group (8.3% and 8.3%) compared with placebo (26.8% and 29.3%) ( Table 2) .
Patients in the granisetron group required significantly less rescue antiemetics than those in the placebo group during 1-24 hours after anaesthesia and the entire 24 hours (Table 2) . Nausea severity scores (NSSs) were not significantly different between the three groups (p > 0.05) ( Table 2) .
The most common untoward adverse events were mild headache and dizziness. No differences in the incidence of adverse events were observed among the groups (p > 0.05) ( Table 3 ).
DISCUSSION
We found that PONV was very common in thyroidectomized patients and low-dose granisetron 20 µg/kg i.v. was effective for the prevention of PONV during the first 24 hours after anaesthesia, without significant adverse events. In this study, the incidence of PONV was 36.6% (0-1 h), 51.2% (1-24 h) and 61.0% (overall, 0-24 h) in the placebo group. And, the administration of granisetron 20 µg/kg i.v. immediately before induction anaesthesia significantly reduced the incidence of PONV from 36.6% to 11.1% (0-1 h) and 61.0% to 30.6% (overall, 0-24 h).
The etiology of PONV after surgery is multifactorial and includes age, sex, weight, history of motion sickness and/or previous PONV, surgical procedure as well as anaesthetic technique. [14] [15] [16] [17] [18] [19] [20] [21] In this study, the three groups were comparable for all factors that might have contributed to PONV and, thus, it may be reasonably suggested that the difference in the incidence of PONV among the groups was attributed to the antiemetic administered.
During thyroidectomy, age range, patient's sex (mostly young or middle-aged women) and intense stimulation of vagal afferents during surgical handling of the neck are considered to increase the incidence of PONV. 3, 4 Dejonckheere and colleagues 3 reported that the incidence of PONV after thyroidectomy was 60%-84%. Recently, Sonner et al reported that, in women patients undergoing thyroid or parathyroid surgery, the incidence Values are mean ± SD or number (%). n = patient numbers. PONV = postoperative nausea and vomiting. No significant differences between groups.
of PONV was 64% with isoflurane and 44% with propofol. 22 In our study, during the first 24 hours postoperative period the incidence of PONV was reported as 61.0% when using enflurane and this value is comparable with the previous studies. 3, 4, 22 Ramosetron, granisetron and odansetron are selective 5-hydroxytryptamine type 3 (5-HT 3 ) receptor antagonists. Granisetron is known to be more potent, and has longeracting activity against cisplatin-induced emesis than ondansetron. 23 Its mechanism of action is both central as well as peripheral (gastrointestinal tract). [24] [25] [26] [27] It blocks 5-HT 3 receptors in the mucosal vagal afferents, thereby inhibiting the afferent arm of the vomiting reflex. 27 Fujii and colleagues [7] [8] [9] demonstrated that 40 µg/kg granisetron reduces the incidence of PONV after breast surgery, middle-ear surgery and thyroidectomy. They also suggested that 40 µg/kg granisetron appears to be the minimum effective dose for preventing PONV in women Values are number (%) or mean ± SD. P 1 = placebo vs granisetron; P 2 = placebo vs ramosetron; P 3 = granisetron vs ramosetron. undergoing middle-ear surgery. 8 In our study, granisetron 20 µg/kg i.v. was found to reduce the incidence of PONV compared to placebo. This is not in accordance with the results of previous studies, [7] [8] [9] which demonstrated that granisetron 20 µg/kg i.v. was not effective for the prevention of PONV. Ramosetron has more potent and longer acting properties than granisetron against cisplatin-induced emesis. 5 The precise mechanism of action of ramosetron remains unclear, but it is thought to behave via the same mechanism as granisetron. 28 In previous studies, ramosetron 0.3 mg was reported as the minimum effective dose for the prevention of PONV and ramosetron 0.3 mg as well as granisetron 3 mg effectively prevented PONV after middle-ear surgery. 11, 12 In our study, the average ramosetron and granisetron dosages used were 0.23 mg (mean weight of 58.2 kg at 4 µg/kg) and 1.2 mg (mean weight of 61.0 kg at 20 µg/kg), respectively. The dosage of ramosetron was similar to that used in previous studies, but in our study, it had no effect in the prevention of PONV. In contrast, the dosage of granisetron was much lower than that in previous studies, but showed superiority over placebo in the prevention of PONV after thyroidectomy. However, it only prevented PONV in 69.4% of patients in the first 24 hours postoperatively, and 30% of patients still suffered from PONV. These results suggest that more effective antiemetic therapy has yet to be determined and this may include the use of a higher ramosetron or granisetron dose and using a combination of antiemetics that have different mechanisms of action. However, when increasing the 5-HT 3 receptor antagonist dosage, we should be wary that the adverse events of the drug will increase simultaneously. Tramer and colleagues reviewed the data for ondansetron and reported that headache was the most common drugrelated adverse event and was dose dependent. 2 In our study, the most common untoward adverse events were headache and dizziness and these were relatively mild. No differences in the incidences of adverse events were observed among the groups (Table 3) .
CONCLUSION
Our study of the efficacy and safety of antiemetic prophylaxis with i.v. granisetron 20 µg/kg and ramosetron
